To identify immune subpopulations associated with response to ICIs, Wei et al. applied mass cytometry on surgically resected melanoma tumors from patients being treated with anti-CTLA4, anti-PD1, or the combination of both, showing that anti-CTLA4 and anti-PD1-induced immune responses are driven by distinct cellular mechanisms [80]. This evidence concerns the gene CTLA4 and melanoma.